Kronik hepatit C tedavisinde yeni seçenekler

Amaç: Kronik hepatit C (KHC) infeksiyonu tüm dünyada siroz ve karaciğer kanserinin en önemli nedenlerinden biridir. Hastaların tespit edilerek tedavi edilmesi bu olumsuz sonuçların ortaya çıkmasını büyük ölçüde önlemektedir. Günümüzde KHC tedavisinde önerilen standart tedavi şeması, pegile-interferon alfa 2a/2b ile birlikte ribavirin kombinasyonundan oluşmaktadır. Yanıtsız hastalarda yeni tedavi seçenekleri gündemdedir. Bu yazıda özellikle yanıtsız ve relaps gelişen hastalardaki tedavi seçeneklerinin değerlendirilmesi amaçlanmıştır. Ana bulgular: Tedaviye yanıt alınamayan ya da relaps gelişen hastalar için, yeni geliştirilen proteaz inhibitörü ilaçlar içinde telaprevir ve boceprevir ön plana çıkan iki ilaçtır. Sonuç: İncelenen son literatür verilerine göre yanıtsız ya da relaps gelişen KHC hastaları için proteaz inhibitörlerini içeren tedavi kombinasyonları yeni umutlar vaad etmektedir.

New options of chronic hepatitis C treatment

Objective: Chronic hepatitis C (CHC) is one of the important reasons of cirrhosis and hepatocellular carcinoma in the world. CHC patients should determine because of treatment of them may be prevent cirrhosis and hepatocellular carcinoma. Now, pegile-interferon 2a/2b and ribavirin combination is standard treatment for CHC. In this review treatment options for relapser or nonresponder CHC patients were evaluated. Main findings: Treatment in nonresponder or relapser patients is difficult due to absent of alternative certain treatment. But recently, new developed protease inhibitors may be new option for them. Telaprevir and boceprevir are two important new protease inhibitors. Conclusion: According to data obtained from the literature, protease inhibitors are promises new hope for relapser or nonresponder CHC patients.

PDF

___

1. Pearlman BL, Sjogren MH. Treatment options for HCV nonresponders and relaps patients. Gastroenterol Hepatol 2010;6:1-12.
2. European Association fort he Study of the Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
3. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-64.
4. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterol 2010;138:116-22.
5. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R et al. Randomized study of peginterferonalpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterol 2010;138:108-15.
6. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
7. Saltoğlu N. Önceki tedaviye yanıtsız/relaps kronik hepatit C hastalarında tedavi ve alternatif tedaviler. Tabak F, Balık İ (ed). Viral Hepatit 2009, 1 baskı, İstanbul Medikal Yayıncılık 2009; 137-150.
8. Patullo V, Heathcote EJ, Wong DKH. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int 2010;4:723-31.
9. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009;58:1662-9.
10. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriquez CM et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterol 2005;128:636-41.
11. Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological imolication. Am J Gastroenterol 2007;102:1237-1243.
12. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC et al. Insulin resistance predicts response to peginterferonalpha/ ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50:712-8.
13. Villa E, Karampatou A, Camma C, Di Leo A, Luongo M, Ferrari A et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterol 2011;140:818-29.
14. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S et al. IL28B polymorphisms, IP-10 viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011;33:1162-72.
15. Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PloS One 2011;6:e17232.
16. Selzner N, Chen L, Borozan I, Edwards A, Heathcote EJ, McGilvray I. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J Hepatol 2008;48:708-13.
17. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78–84.
18. Poordad F, Kambili C. Predictability of response: positive and negative predictive values of rapid and early virologic responses to peginterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston, Massachusetts. Abstract 305. Avaible at: http://www.clinicaloptions.com/Hepatitis/
19. Shiffman ML, Pappas S, Bacon B, Godofsky E, Nelson D, Harley H et al. Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with peginterferon alfa-2a (40KD) plus ribavirin: findings from ACCELERATE [abstract 340]. Hepatology 2006; 44:361A.
20. Floreani A, Cazzagon N, Furlan P, Baldovin T, Egoue J, Antoniazzi S et al. Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment. Eur J Gastroenterol Hepatol 2011;23:711-5.
21. Akhan SC, Gürel E, Sayan M. Sustained virologic response of nonresponder hepatitis C virus patients with retreatment. Indian J Pathol Microbiol 2011;54:81-4.
22. Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschênes M, Marotta PJ et al. Retreatment with peginterferon alfa2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon based therapy. Can J Gastroenterol 2009;23:180-4.
23. Gonçales FL Jr, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R et al. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? BMC Infect Dis 2010;10:212.
24. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J med 2011;364:1195-1206.
25. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. Boceprevir for previous treated chronic HCV genotype 1 infection. N Eng J Med 2011; 364:1207-1217.
26. Zeuzem S, Barnard RJ, Howe JA et al. Boceprevir resistanceassociated variants (RAVs) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin. Hepatol 2011;54:S4 (P-9).
27. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
28. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
29. Zeuzem S, Barnard RJ, Howe JA, Ogert RA, Ralston R, Boparai N et al. Boceprevir resistance-associated variants (RAVs) are observed more frequently in HCV (GT1)-infected patients with poor response to peg-interferon alfa-2b/ribavirin. Hepatol 2011;54:S4,P-9.
30. Sullivan JC, De Meyer S, Bartels DJ,Dierynck I, Zhang E, Spanks J et al. Evolution of treatment-emergent resistant variants in telaprevir phase. Hepatol 2011;54:S4,P-8.